We look for answers in unexpected places & vigorously test our hypotheses to deliver ground-breaking advances to patients.

Careful Planning for Success

Inmedix specializes in understanding key diagnostics

Inmedix successfully secured FDA clearance for its CloudHRV^® System diagnostic in January 2025 and is launching the product in June 2025.  CloudHRV reports precision heart rate variability (HRV) indices in the clinic within 10-15 seconds from a high fidelity, 5-minute, limb-lead ECG at rest using calculations completed in the cloud. 

This precision, medical-grade HRV quantifies the two main regulatory aspects of the autonomic nervous system (ANS) within the central brain: the parasympathetic (rest/restorative) and sympathetic (fight-or-flight) components.

Inmedix is committed to exploring the utility of CloudHRV and ANS neuromodulation in rigorous clinical trials and expanding access to this diagnostic worldwide.

NOTICE

This website contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies and product capabilities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation, progress of development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures.  All forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.